Results 181 to 190 of about 165,526 (354)

Jaagsiekte sheep retrovirus infection of lung slice cultures [PDF]

open access: yes, 2015
A Abbott   +66 more
core   +1 more source

CRISPR Technology in Disease Management: An Updated Review of Clinical Translation and Therapeutic Potential

open access: yesCell Proliferation, EarlyView.
CRISPR‐Cas systems offer transformative genome editing capabilities for precise manipulation of cellular genes. This enables two main therapeutic avenues: ex vivo modification of patient cells for re‐transplantation or direct in vivo gene targeting via advanced delivery methods.
Bahareh Farasati Far   +4 more
wiley   +1 more source

Discovery of unfixed endogenous retrovirus insertions in diverse human populations

open access: yesProceedings of the National Academy of Sciences of the United States of America, 2016
Julia H Wildschutte   +5 more
semanticscholar   +1 more source

Type I interferon signalling and interferon‐responsive microglia in health and disease

open access: yesThe FEBS Journal, EarlyView.
Recent insights reveal that type I interferon (IFN‐I) signalling plays critical roles in the nervous system beyond antiviral defence. Dysregulated IFN‐I activity is increasingly linked to neurological dysfunction and neurodegeneration, with microglia as central mediators. This review explores the broader impact of IFN‐I signalling on the nervous system
Jose P. Lopez‐Atalaya   +1 more
wiley   +1 more source

Long‐acting injectable cabotegravir and rilpivirine in observational cohort studies: A systematic review on virological failure, resistance and re‐suppression outcomes in virally suppressed individuals living with HIV

open access: yesHIV Medicine, EarlyView.
Abstract Introduction Randomized controlled trial evidence suggests that long‐acting injectable (LA‐I) cabotegravir and rilpivirine (CAB+RPV) has similar virological failure (VF) rates to daily oral therapy, but clinical practice evidence is lacking. Integrase inhibitor (INI) resistance may limit future therapy.
Kyle Ring   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy